Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2013;8(1):e54522.
doi: 10.1371/journal.pone.0054522. Epub 2013 Jan 30.

Glucuronidation by UGT1A1 is the dominant pathway of the metabolic disposition of belinostat in liver cancer patients

Ling-Zhi Wang  1 , Jacqueline Ramírez, Winnie Yeo, Mei-Yi Michelle Chan, Win-Lwin Thuya, Jie-Ying Amelia Lau, Seow-Ching Wan, Andrea Li-Ann Wong, Ying-Kiat Zee, Robert Lim, Soo-Chin Lee, Paul C Ho, How-Sung Lee, Anthony Chan, Sherry Ansher, Mark J Ratain, Boon-Cher Goh
Affiliations
Clinical Trial

Glucuronidation by UGT1A1 is the dominant pathway of the metabolic disposition of belinostat in liver cancer patients

Ling-Zhi Wang et al. PLoS One. 2013.

Erratum in

  • PLoS One. 2014;9(1). doi:10.1371/annotation/df796504-a2ea-4807-a412-85985bb2550b

Abstract

Belinostat is a hydroxamate class HDAC inhibitor that has demonstrated activity in peripheral T-cell lymphoma and is undergoing clinical trials for non-hematologic malignancies. We studied the pharmacokinetics of belinostat in hepatocellular carcinoma patients to determine the main pathway of metabolism of belinostat. The pharmacokinetics of belinostat in liver cancer patients were characterized by rapid plasma clearance of belinostat with extensive metabolism with more than 4-fold greater relative systemic exposure of major metabolite, belinostat glucuronide than that of belinostat. There was significant interindividual variability of belinostat glucuronidation. The major pathway of metabolism involves UGT1A1-mediated glucuronidation and a good correlation has been identified between belinostat glucuronide formation and glucuronidation of known UGT1A1 substrates. In addition, liver microsomes harboring UGT1A1*28 alleles have lower glucuronidation activity for belinostat compared to those with wildtype UGT1A1. The main metabolic pathway of belinostat is through glucuronidation mediated primarily by UGT1A1, a highly polymorphic enzyme. The clinical significance of this finding remains to be determined.

Trial registration: ClinicalTrials.gov NCT00321594.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist. Please note that belinostat is a Topotarget product. This does not alter the authors’ adherence to all the PLOS ONE policies on sharing data and materials.

Figures

Figure 1
Figure 1. Identification of belinostat metabolites in human plasma using HPLC-UV at maximum absorption wavelength (λ = 268 nm).
Chromatogram at day 5 and day 22 (A); day1(B).
Figure 2
Figure 2. Belinostat metabolism pathway in human plasma with glucuronidation of belinostat as the dominant metabolism.
Figure 3
Figure 3. Cytotoxicity and acetylation activity on HepG2.
a: belinostat incubation; b: belinostat-G incubation; (templates for concentrations added (lower) and results of 24-well dose-increasing concentrations on HepG2 Cells (upper). c: MTS results for belinostat (IC50 = 6.4 µM) and belinostat-G (cannot be converged). d:Belinostat acetylation activity on HepG2 cells (western blot). A: Acetyl histone 3 increased with dose increment after 5 h incubation; B: Kinetic changes of acetyl histone 3 with time increment at 10 µM.
Figure 4
Figure 4. Enzyme stability test in a panel of 14 UGT isoforms after 2 h incubation at 37°C (A); Time course of glucuronidation of belinostat by UGT1A1supersomes at 37°C (B).
Figure 5
Figure 5. Enzyme kinetics of glucuronidation of belinostat by UGT1A1.
The apparent Km and Vmax values for the glucuronide formation were 99.6 µM and 353.1 pmol/min/mg protein, respectively.
Figure 6
Figure 6. Association between glucuronidation of belinostat and UGT1A1 substrates (A, B, and C).
A: Bilirubin-G; B: thyroxine-4-G/CPT-11; C: SN38-G/CPT11.
Figure 7
Figure 7. UGT1A1 expression on belinostat glucuronidation and impact of the common UGT1A1*28 promoter polymorphism.
A: Correlation of belinostat glucuronide formation with UGT1A1 expression in human liver microsomes; B: Belinostat glucuronide formation by human liver microsomes according to wild-type, heterozygous and homozygous UGT1A1*28 genotypes.
See this image and copyright information in PMC

References

    1. Marks PA, Richon VM, Miller T, Kelly WK (2004) Histone deacetylase inhibitors. Adv Cancer Res 91: 137–168. - PubMed
    1. Gray SG, Qian CN, Furge K, Guo X, The BT (2004) Microarray profiling of the effects of histone deacetylase inhibitors on gene expression in cancer cell lines. Int J Oncol 24: 773–795. - PubMed
    1. Mitsiades CS, Mitsiades NS, Mcmullan CJ, Poulaki V, Shringarpure R, et al. (2004) Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. Proc Natl Acad Sci 101: 540–545. - PMC - PubMed
    1. Peart MJ, Smyth GK, van Laar RK, Bowtell DD, Richon VM, et al. (2005) Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors. Proc Natl Acad Sci 102: 3697–3702. - PMC - PubMed
    1. Tanji N, Ozawa A, Kikugawa T, Miura N, Sasaki T, et al. (2011) Potential of histone deacetylase inhibitors for bladder cancer treatment. Expert Rev Anticancer Ther 1: 959–965. - PubMed

Publication types

MeSH terms

Associated data